A novel restricted access-anion exchange organic monolithic phase for determining homocysteine and homocysteic acid in cerebrospinal fluid samples obtained from Alzheimer's disease patients by in-tube SPME-LC-MS/MS.

BACKGROUND

High circulating concentrations of homocysteine (Hcy), a sulfur-containing amino acid, and homocysteic acid (HCA), an Hcy oxidized derivative, are an independent risk factor for developing Alzheimer's disease (AD), a neurodegenerative disorder that causes progressive cognitive decline. Therefore, these two endogenous compounds might be potential AD biomarkers. Nevertheless, few studies have attempted to quantify Hcy and HCA in the cerebrospinal fluid (CSF), the best validated fluid for evaluating neurodegenerative disorders.

RESULTS

Here, a novel restricted access-anion exchange organic monolithic phase was synthetized and used as extractive phase during in-tube SPME to analyze Hcy and HCA in CSF samples by LC-MS/MS. The innovative monolithic sorbent is porous and permeable, bears anion exchange groups that selectively extract the target analytes, and displays hydrophilic groups that restrict the access and exclude up to 90 % of macromolecules. Optimization of the synthesis parameters and evaluation of the in-tube SPME parameters improved the monolithic phase efficiency in extracting Hcy and HCA. Validation of the proposed method showed that it is linear from 8 to 250 ng mL Hcy and from 5 to 150 ng mL HCA, has adequate accuracy and precision, no significant matrix effect, and prevents carryover. Application of this innovative method to analyze CSF samples obtained from patients with AD, patients with mild cognitive impairment (MCI), or healthy controls revealed elevated Hcy levels in AD and MCI patients, with considerable discriminatory potential.

SIGNIFICANCE AND NOVELTY

This is the first organic monolith with restricted access-anion exchange properties to be developed for in-tube SPME application. Furthermore, the proposed method addresses the need of a robust microextraction method for the determination of Hcy and HCA in cerebrospinal fluid samples. The findings also suggest Hcy as a potential AD biomarker, motivating further studies on the role this endogenous compound plays in early diagnosis and disease progression.